333 related articles for article (PubMed ID: 26271598)
1. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.
Planagumà A; Domènech T; Pont M; Calama E; García-González V; López R; Aulí M; López M; Fonquerna S; Ramos I; de Alba J; Nueda A; Prats N; Segarra V; Miralpeix M; Lehner MD
Pulm Pharmacol Ther; 2015 Oct; 34():37-45. PubMed ID: 26271598
[TBL] [Abstract][Full Text] [Related]
2. The combined CXCR1/CXCR2 antagonist CXCL8(3-74)K11R/G31P blocks neutrophil infiltration, pyrexia, and pulmonary vascular pathology in endotoxemic animals.
Gordon JR; Li F; Zhang X; Wang W; Zhao X; Nayyar A
J Leukoc Biol; 2005 Dec; 78(6):1265-72. PubMed ID: 16204619
[TBL] [Abstract][Full Text] [Related]
3. Rabbit neutrophil chemotactic protein (NCP) activates both CXCR1 and CXCR2 and is the functional homologue for human CXCL6.
Catusse J; Struyf S; Wuyts A; Weyler M; Loos T; Gijsbers K; Gouwy M; Proost P; Van Damme J
Biochem Pharmacol; 2004 Nov; 68(10):1947-55. PubMed ID: 15476666
[TBL] [Abstract][Full Text] [Related]
4. Porcine CXCR1/2 antagonist CXCL8
Wang X; Li Y; Li L; Jiao Z; Liu X; Cheng G; Gu C; Hu X; Zhang W
Sci Rep; 2020 Jan; 10(1):1210. PubMed ID: 31988368
[TBL] [Abstract][Full Text] [Related]
5. Development of a systemically-active dual CXCR1/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat.
Garau A; Bertini R; Mosca M; Bizzarri C; Anacardio R; Triulzi S; Allegretti M; Ghezzi P; Villa P
Eur Cytokine Netw; 2006 Mar; 17(1):35-41. PubMed ID: 16613761
[TBL] [Abstract][Full Text] [Related]
6. Cloning and characterization of guinea pig CXCR1.
Takahashi M; Jeevan A; Sawant K; McMurray DN; Yoshimura T
Mol Immunol; 2007 Feb; 44(5):878-88. PubMed ID: 16712933
[TBL] [Abstract][Full Text] [Related]
7. A novel flow cytometric assay of human whole blood neutrophil and monocyte CD11b levels: upregulation by chemokines is related to receptor expression, comparison with neutrophil shape change, and effects of a chemokine receptor (CXCR2) antagonist.
Nicholson GC; Tennant RC; Carpenter DC; Sarau HM; Kon OM; Barnes PJ; Salmon M; Vessey RS; Tal-Singer R; Hansel TT
Pulm Pharmacol Ther; 2007; 20(1):52-9. PubMed ID: 16406722
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2.
Maeda DY; Peck AM; Schuler AD; Quinn MT; Kirpotina LN; Wicomb WN; Fan GH; Zebala JA
J Med Chem; 2014 Oct; 57(20):8378-97. PubMed ID: 25254640
[TBL] [Abstract][Full Text] [Related]
9. CXCR1 and CXCR2 are rapidly down-modulated by bacterial endotoxin through a unique agonist-independent, tyrosine kinase-dependent mechanism.
Khandaker MH; Xu L; Rahimpour R; Mitchell G; DeVries ME; Pickering JG; Singhal SK; Feldman RD; Kelvin DJ
J Immunol; 1998 Aug; 161(4):1930-8. PubMed ID: 9712063
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor.
Widdowson KL; Elliott JD; Veber DF; Nie H; Rutledge MC; McCleland BW; Xiang JN; Jurewicz AJ; Hertzberg RP; Foley JJ; Griswold DE; Martin L; Lee JM; White JR; Sarau HM
J Med Chem; 2004 Mar; 47(6):1319-21. PubMed ID: 14998320
[TBL] [Abstract][Full Text] [Related]
11. CXCL8((3-73))K11R/G31P antagonizes ligand binding to the neutrophil CXCR1 and CXCR2 receptors and cellular responses to CXCL8/IL-8.
Li F; Zhang X; Gordon JR
Biochem Biophys Res Commun; 2002 May; 293(3):939-44. PubMed ID: 12051749
[TBL] [Abstract][Full Text] [Related]
12. The selective CXCR2 antagonist SB272844 blocks interleukin-8 and growth-related oncogene-alpha-mediated inhibition of spontaneous neutrophil apoptosis.
Glynn PC; Henney E; Hall IP
Pulm Pharmacol Ther; 2002; 15(2):103-10. PubMed ID: 12090783
[TBL] [Abstract][Full Text] [Related]
13. Decreased CXCR1 and CXCR2 expression on neutrophils in anti-neutrophil cytoplasmic autoantibody-associated vasculitides potentially increases neutrophil adhesion and impairs migration.
Hu N; Westra J; Rutgers A; Doornbos-Van der Meer B; Huitema MG; Stegeman CA; Abdulahad WH; Satchell SC; Mathieson PW; Heeringa P; Kallenberg CG
Arthritis Res Ther; 2011; 13(6):R201. PubMed ID: 22152684
[TBL] [Abstract][Full Text] [Related]
14. Downmodulation of CXCL8/IL-8 receptors on neutrophils after recruitment in the airways.
Pignatti P; Moscato G; Casarini S; Delmastro M; Poppa M; Brunetti G; Pisati P; Balbi B
J Allergy Clin Immunol; 2005 Jan; 115(1):88-94. PubMed ID: 15637552
[TBL] [Abstract][Full Text] [Related]
15. Actin filaments are involved in the regulation of trafficking of two closely related chemokine receptors, CXCR1 and CXCR2.
Zaslaver A; Feniger-Barish R; Ben-Baruch A
J Immunol; 2001 Jan; 166(2):1272-84. PubMed ID: 11145710
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist.
Dwyer MP; Yu Y; Chao J; Aki C; Chao J; Biju P; Girijavallabhan V; Rindgen D; Bond R; Mayer-Ezel R; Jakway J; Hipkin RW; Fossetta J; Gonsiorek W; Bian H; Fan X; Terminelli C; Fine J; Lundell D; Merritt JR; Rokosz LL; Kaiser B; Li G; Wang W; Stauffer T; Ozgur L; Baldwin J; Taveras AG
J Med Chem; 2006 Dec; 49(26):7603-6. PubMed ID: 17181143
[TBL] [Abstract][Full Text] [Related]
17. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration.
White JR; Lee JM; Young PR; Hertzberg RP; Jurewicz AJ; Chaikin MA; Widdowson K; Foley JJ; Martin LD; Griswold DE; Sarau HM
J Biol Chem; 1998 Apr; 273(17):10095-8. PubMed ID: 9553055
[TBL] [Abstract][Full Text] [Related]
18. Differential Effects of Posttranslational Modifications of CXCL8/Interleukin-8 on CXCR1 and CXCR2 Internalization and Signaling Properties.
Vacchini A; Mortier A; Proost P; Locati M; Metzemaekers M; Borroni EM
Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30486423
[TBL] [Abstract][Full Text] [Related]
19. Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases.
Busch-Petersen J
Curr Top Med Chem; 2006; 6(13):1345-52. PubMed ID: 16918453
[TBL] [Abstract][Full Text] [Related]
20. Expression and function of the chemokine receptors CXCR1 and CXCR2 in sepsis.
Cummings CJ; Martin TR; Frevert CW; Quan JM; Wong VA; Mongovin SM; Hagen TR; Steinberg KP; Goodman RB
J Immunol; 1999 Feb; 162(4):2341-6. PubMed ID: 9973513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
